Yelin Lapidot Holdings Management Ltd. Lowers Position in Arvinas, Inc. (NASDAQ:ARVN)

Yelin Lapidot Holdings Management Ltd. trimmed its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 5.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,873 shares of the company’s stock after selling 2,630 shares during the quarter. Yelin Lapidot Holdings Management Ltd.’s holdings in Arvinas were worth $899,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in ARVN. Assenagon Asset Management S.A. purchased a new position in Arvinas in the third quarter valued at $3,442,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after purchasing an additional 440 shares in the last quarter. abrdn plc boosted its position in Arvinas by 27.8% during the third quarter. abrdn plc now owns 78,585 shares of the company’s stock worth $1,936,000 after purchasing an additional 17,093 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Arvinas by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,203 shares of the company’s stock valued at $325,000 after purchasing an additional 5,163 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Arvinas in the third quarter valued at approximately $350,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Stock Up 0.7 %

NASDAQ ARVN opened at $17.26 on Friday. Arvinas, Inc. has a 52 week low of $16.07 and a 52 week high of $51.51. The business’s fifty day simple moving average is $18.37 and its 200-day simple moving average is $22.72. The firm has a market cap of $1.19 billion, a PE ratio of -6.23 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the business posted ($2.53) EPS. Research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ARVN shares. Stifel Nicolaus reduced their price objective on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Stephens began coverage on Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective on the stock. Barclays reduced their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Oppenheimer lifted their price target on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Arvinas presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Insider Activity at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the transaction, the insider now owns 159,121 shares of the company’s stock, valued at $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,572 shares of company stock worth $695,030. Insiders own 5.23% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.